Introduction
Methods
Data Sources and Search
Study Selection
Data Extraction and Quality Assessment
Data Synthesis and Analysis
Results
Search Results
Journal | Year | Patients, n
| Start of drug administration | Mean duration of drug administration | |
---|---|---|---|---|---|
Landiolol | Control | ||||
J Thorac Cardiovasc Surg [18] | 2011 | 70 | 70 | At the time of central anastomosis | 48 h |
J Thorc Cardiovasc Surg [19] | 2012 | 77 | 34 | At the completion of central anastomosis | 72 h |
J Cardiovasc Surg [20] | 2012 | 36 | 34 | In the ICU immediately after surgery | Until resumption of oral intake (50 h) |
Asian Cardiovasc Thorac Ann [21] | 2013 | 68 | 68 | Immediately after induction of anesthesia | 48 h |
Ann Thorac Cardiovasc Surg [22] | 2013 | 21 | 22 | At the start of ICU admission | Until resumption of oral intake (1.6 days) |
Int Heart J [23] | 2012 | 30 | 30 | At the start of ICU admission | 72 h |
Study Characteristics
References | Groups | Surgery | Treatment group | Control group | Definition of atrial fibrillation |
---|---|---|---|---|---|
Sezai et al. [18] | 2 | On-pump CABG | Landiolol | Placebo | ≥5 min or a requirement for treatment because of hemodynamic changes |
Sezai et al. [19] | 3 | On-pump CABG | Landiolol | Placebo | ≥5 min or a requirement for treatment because of hemodynamic changes |
Landiolol and oral bisoprolol | ≥5 min or a requirement for treatment because of hemodynamic changes | ||||
Fujii et al. [20] | 2 | Off-pump CABG | Landiolol and oral carvedilol after extubation | No treatment and oral carvedilol after extubation | Irregular narrow-complex rhythm with absence of a discrete P wave lasting >10 min, or a requirement for treatment because of intolerable symptoms or hemodynamic deterioration |
Ogawa et al. [21] | 2 | Off-pump CABG | Landiolol | No treatment | ≥10 min |
Nagaoka et al. [22] | 2 | Off-pump CABG | Landiolol | Diltiazem | New-onset atrial fibrillation or atrial flutter requiring treatment or lasting >5 min |
Sakaguchi et al. [23] | 2 | Valve replacement/valvuloplasty | Landiolol | No treatment | ≥1 min |
References | Groups | Landiolol dose | Control drug dose |
---|---|---|---|
Sezai et al. [18] | 2 | 2 µg/kg/min ci | Saline |
Sezai et al. [19] | 3 | 5 µg/kg/min ci initially | Saline |
5 µg/kg/min ci and oral or nasogastric administration of bisoprolol (2.5 mg/day) from the day after surgery | |||
Fujii et al. [20] | 2 | 6.3 µg/kg/min ci (mean value) followed by oral carvedilol (2.5–5 mg/day) | Oral carvedilol (2.5–5 mg/day) after extubation and resumption of oral intake |
Ogawa et al. [21] | 2 | 3–5 µg/kg/min ci | No drug given |
Nagaoka et al. [22] | 2 | 0.5–1 µg/kg/min ci | Diltiazem, 0.5–1 µg/kg/min ci |
Sakaguchi et al. [23] | 2 | 10 µg/kg/min ci initially, titrated according to heart rate and blood pressure (2.5–10 µg/kg/min) | No drug given |
References | Adequate sequence generation | Allocation concealment used | Blinding | Concurrent therapies similar | Incomplete outcome data addressed | Uniform and explicit outcome definitions | Free of selective outcome reporting | Free of other bias | Overall risk of bias |
---|---|---|---|---|---|---|---|---|---|
Sezai et al. [18] | Yes (lottery method) | Yes (double-blind) | Yes | Unclear | Yes | Yes | Yes | Yes | Low |
Sezai et al. [19] | Yes (lottery method) | Yes (double-blind) | Yes | Unclear | Unclear | Yes | Yes | Yes | Low |
Fujii et al. [20] | Yes (computer-generated randomization table) | Yes (computed) | No | Yes | Unclear | Yes | Unclear | Yes | Low |
Ogawa et al. [21] | Unclear | Unclear | No | Yes | Unclear | Yes | Unclear | Yes | Low |
Nagaoka et al. [22] | Yes (computer-generated table) | Yes (computed) | No | Unclear | Unclear | Yes | Unclear | Yes | Low |
Sakaguchi et al. [23] | Yes (coin toss method) | Unclear | No | Unclear | Unclear | Yes | Unclear | Yes | Low |